Tocagen Granted ApolloBio Greater China Rights of Immunotherapy Candidate for $127 Million
publication date: Apr 23, 2018
Tocagen Inc. licensed its Phase III stage candidate Toca 511 & Toca FC to ApolloBio. The deal includes an upfront payment of $16 million, a near-term $4 million milestone after clinical trials and other additional future payments totaling up to $107 million. The deal is worth of $127 million in total. According to the deal terms, ApolloBio will gain exclusive rights of Toca 511 & Toca FC and will be responsible for developing and commercializing the candidate in Greater China, including mainland China, Hong Kong, Macao and Taiwan. More details....
Stock Symbol: (Nasdaq: TOCA) (NEEQ: 430187)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.